SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 101 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $43,720,000 | +11.3% | 2,287,782 | 0.0% | 1.53% | +10.2% |
| Q2 2021 | $39,281,000 | -23.2% | 2,287,782 | 0.0% | 1.39% | -20.1% |
| Q1 2021 | $51,155,000 | +0.5% | 2,287,782 | 0.0% | 1.74% | +6.1% |
| Q4 2020 | $50,880,000 | +50.7% | 2,287,782 | 0.0% | 1.64% | +40.2% |
| Q3 2020 | $33,768,000 | -0.4% | 2,287,782 | 0.0% | 1.17% | -21.7% |
| Q2 2020 | $33,905,000 | +325.8% | 2,287,782 | +215.2% | 1.49% | +174.6% |
| Q1 2020 | $7,962,000 | +262.7% | 725,782 | +190.3% | 0.54% | +337.9% |
| Q4 2019 | $2,195,000 | -26.5% | 250,000 | -37.5% | 0.12% | -42.9% |
| Q3 2019 | $2,988,000 | +269.8% | 400,000 | +300.0% | 0.22% | +141.1% |
| Q3 2018 | $808,000 | +15.1% | 100,000 | 0.0% | 0.09% | +13.9% |
| Q2 2018 | $702,000 | -50.7% | 100,000 | 0.0% | 0.08% | -48.0% |
| Q1 2018 | $1,423,000 | +62.4% | 100,000 | 0.0% | 0.15% | -5.0% |
| Q4 2017 | $876,000 | -25.1% | 100,000 | 0.0% | 0.16% | -39.8% |
| Q3 2017 | $1,170,000 | -64.2% | 100,000 | -57.3% | 0.27% | -65.8% |
| Q2 2017 | $3,272,000 | +1.8% | 234,220 | 0.0% | 0.78% | +10.8% |
| Q1 2017 | $3,213,000 | +91.4% | 234,220 | 0.0% | 0.70% | +8.2% |
| Q4 2016 | $1,679,000 | -52.7% | 234,220 | 0.0% | 0.65% | -59.2% |
| Q3 2016 | $3,551,000 | +53.9% | 234,220 | 0.0% | 1.59% | -22.2% |
| Q2 2016 | $2,307,000 | -26.1% | 234,220 | 0.0% | 2.05% | -33.0% |
| Q1 2016 | $3,120,000 | – | 234,220 | – | 3.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |